Current concepts in antimicrobial therapy against select gram-positive organisms: Methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci

Mayo Clinic Proceedings

Volumn 86, Issue 12, 2011, Pages 1230-1243

  Rivera, Ana Maria ^a   Boucher, Helen W ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; CEFPODOXIME; CEFTAROLINE; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; DOXYCYCLINE; FOSFOMYCIN; LEVOFLOXACIN; LINEZOLID; MACROLIDE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTHRALGIA; BLOODSTREAM INFECTION; BONE MARROW SUPPRESSION; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED INFECTION; COMMUNITY ACQUIRED PNEUMONIA; CONFERENCE PAPER; CONSTIPATION; DIARRHEA; DISEASE TRANSMISSION; DRUG BIOAVAILABILITY; DRUG COST; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; ENDOCARDITIS; ENTEROCOCCAL INFECTION; FOAMY URINE; GRAM POSITIVE INFECTION; HEADACHE; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; INJECTION SITE PAIN; INJECTION SITE REACTION; INSOMNIA; LACTIC ACIDOSIS; LOEFFLER PNEUMONIA; MENINGITIS; METABOLIC ACIDOSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORBIDITY; MORTALITY; MYALGIA; MYOPATHY; NAUSEA; NEPHROTOXICITY; NONHUMAN; OPTIC NEURITIS; PENICILLIN RESISTANCE; PERIPHERAL NEUROPATHY; PNEUMOCOCCAL INFECTION; PNEUMONIA; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SKIN INFECTION; SKIN STRUCTURE; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; URINE; VANCOMYCIN RESISTANT ENTEROCOCCUS; VESTIBULAR NEURONITIS; VOMITING;

EID: 83155173447     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2011.0514     Document Type: Conference Paper

References (155)

1. Boucher HW, Corey GR. Epidemiology of methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(suppl 5):S344-S349. (Pubitemid 351717321)
2. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America [published corrections appear in Clin Infect Dis. 2010;50(3):457 and 2010;50(7):1079 dosage error in article text]. Clin Infect Dis. 2009;49(1):1-45.
3. Seybold U, Kourbatova EV, Johnson JG, et al. Emergence of community-associated methicillin-resistant Staphylococcus aureus USA300 genotype as a major cause of health care-associated blood stream infections. Clin Infect Dis. 2006;42(5):647-656. (Pubitemid 43271378)
4. Gorwitz RJ. A review of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. Pediatr Infect Dis J. 2008;27(1):1-7.
5. Centers for Disease Control and Prevention (CDC). Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus-Minnesota and North Dakota, 1997-1999. Arch Dermatol.1999;135(12):1566-1568.
6. Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for panton-valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002;359(9308):753-759.
7. Francis JS, Doherty MC, Lopatin U, et al. Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the panton-valentine leukocidin genes. Clin Infect Dis. 2005;40(1):100-107.
8. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med. 2005;352(14):1436-1444.
9. Boucher HW, Sakoulas G. Perspectives on daptomycin resistance, with emphasis on resistance in Staphylococcus aureus. Clin Infect Dis. 2007;45(5):601-608. (Pubitemid 47328642)
10. Charles PGP, Ward PB, Johnson PDR, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38(3):448-451. (Pubitemid 38200128)
11. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18-e55.
12. Daum RS. Skin and soft-tissue infections caused by methicillinresistant Staphylococcus aureus [published correction appears in N Engl J Med. 2007;357(13):1357 dosage error in text]. N Engl J Med. 2007;357(4):380-390.
13. Moran GJ, Krishnadasan A, Gorwitz RJ, et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006;355(7):666-674.
14. Cook HA, Furuya EY, Larson E, Vasquez G, Lowy FD. Heterosexual transmission of community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2007;44(3):410-413. (Pubitemid 46151062)
15. Chua K, Laurent F, Coombs G, Grayson ML, Howden BP. Not community- associated methicillin-resistant Staphylococcus aureus (CA-MRSA)! A clinician's guide to community MRSA-its evolving antimicrobial resistance and implications for therapy. Clin Infect Dis. 2011;52(1):99-114.
16. Otter JA, French GL. Molecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus in Europe. Lancet Infect Dis. 2010;10(4):227-239.
17. Deleo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated methicillin-resistant Staphylococcus aureus. Lancet. 2010;375(9725):1557-1568.
18. Klevens RM, Morrison MA, Nadle J, et al. Active Bacterial Core Surveillance (ABCs) MRSA Investigators. Invasive methicillin-resistant Staphylo-coccus aureus infections in the United States. JAMA. 2007;298(15):1763-1771.
19. Voyich JM, Otto M, Mathema B, et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis. 2006;194(12):1761-1770. (Pubitemid 44902009)
20. Strategies using off-patent antibiotics for methicillin resistant S. aureus "STOP MRSA" ClinicalTrials.gov Web site. http://www. clinicaltrials.gov/ct2/show/NCT00729937?term=talan+mrsa&rank=1). Accessed October 24, 2011.
21. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis. 2003;37(9):1257-1260. (Pubitemid 37372517)
22. Moellering RC. Current treatment options for community-acquired methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis. 2008;46(7):1032-1037.
23. Rybak MJ, Lomaestro BM, Rotscahfer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists [published correction appears in Clin Infect Dis. 2009;49(9):1465]. Clin Infect Dis. 2009; 49(3):325-327.
24. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 2 investigators. CANVAS 2: The second phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(suppl 4):iv53-iv65.
25. Rice LB. The clinical consequences of antimicrobial resistance. Curr Opin Microbiol. 2009;12(5):476-481.
26. Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193-200. (Pubitemid 351269157)
27. Lodise TP, Graves J, Evans A, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008;52(9):3315-3320.
28. Sakoulas G, Moellering RC. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis. 2008;46(suppl 5):S360-S367. (Pubitemid 351717323)
29. Steinkraus G, White R, Friedrich L. Vancomycin MIC creep in nonvancomycin- intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05. J Antimicrob Chemother. 2007;60(4):788-794. (Pubitemid 47434257)
30. Rybak MJ, Leonard SN, Rossi KL, Cheung CM, Sadar HS, Jones RN. Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol. 2008;46(9):2950-2954.
31. Rehm SJ, Boucher H, Levine D, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother. 2008;62(6):1413-1421.
32. Tenover FC, Moellering RC Jr. The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44(9):1208-1215. (Pubitemid 46651246)
33. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42(6):2398-2402. (Pubitemid 38747480)
34. Patel M. Community-associated meticillin-resistant Staphylococcus aureus infections: epidemiology, recognition and management. Drugs. 2009; 69(6):693-716.
35. Horne KC, Howden BP, Grabsch EA, et al. Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillinresistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA. Antimicrob Agents Chemother. 2009;53(8):3447-3452.
36. Holland TL, Fowler VG Jr. Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet [editorial]? J Infect Dis. 2011;204(3):329-331.
37. Holmes NE, Turnidge JD, Munckhof WJ, et al. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J Infect Dis. 2011;204(3):340-347.
38. Kollef MH. Limitations of vancomycin in the management of resistant Staphylococcal infections. Clin Infect Dis. 2007;45(suppl 3):S191-S195. (Pubitemid 47378906)
39. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. Highdose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166(19):2138-2144. (Pubitemid 44631403)
40. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef MH. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther. 2007;29(6):1107-1115. (Pubitemid 47208584)
41. Bardone MR, Paternoster M, Coronelli C. Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. SP. II: extraction and chemical characterization. J Antibiot (Tokyo). 1978;31(3):170-177. (Pubitemid 8326005)
42. Courvalin P. Vancomycin resistance in gram-positive cocci. Clin Infect Dis. 2006;42(suppl 1):S25-S34. (Pubitemid 41832062)
43. Gould FK, Brindle R, Chadwick PR, et al. Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. J Antimicrob Chemother. 2009;63(5):849-861.
44. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49(6):2260-2266.
45. Kollef MH, Rello J, Cammarata SK, Croos-Dabrera RV, Wunderink RG. Clinical cure and survival in gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin. Intensive Care Med. 2004;30(3):388-394. (Pubitemid 38375611)
46. Cruciani M, Gatti G, Lazzarini L, et al. Penetration of vancomycin into human lung tissue. J Antimicrob Chemother. 1996;38(5):865-869. (Pubitemid 26413723)
47. Honeybourne D, Tobin C, Jevons G, Andrews J, Wise R. Intrapulmonary penetration of linezolid. J Antimicrob Chemother. 2003;51(6):1431-1434. (Pubitemid 36748935)
48. Boselli E, Breilh D, Rimmelé T, et al. Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia. Crit Care Med. 2005;33(7):1529-1533. (Pubitemid 40980608)
49. Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother. 2005;56(5):923-929. (Pubitemid 41631919)
50. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48(2):203-212.
51. Lawrence KR, Adra M, Gillman PK. Serotonin toxicity associated with the use of linezolid: a review of postmarketing data. Clin Infect Dis. 2006;42(11):1578-1583.
52. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006;43(2):180-187.
53. Lin YH, Wu VC, Tsai I. High frequency of linezolid-associated thrombocytopenia among patients with renal insufficiency. Int J Antimicrob Agents. 2006;28(4):345-351. (Pubitemid 44402995)
54. Palenzuela L, Hahn NM, Nelson PR Jr, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis. 2005;40(12):e113-e116.
55. Lee E, Burger S, Melton C, Mullen M, Warren F, Press R. Linezolid- associated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis. 2003;37(10):1389-1391. (Pubitemid 37433638)
56. Farrell DJ, Mendes RE, Ross JE, Jones RN. Linezolid surveillance program results for 2008 (LEADER program for 2008). Diagn Microbiol Infect Dis. 2009;65(4):392-403.
57. Tsiodras S, Gold HS, Sakoulas G, et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet. 2001;358(9277):207-208. (Pubitemid 32718546)
58. Morales G, Picazo JJ, Baos E, et al. Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis. 2010;50(6):821-825.
59. Cosgrove SE, Fowler VG. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(suppl 5):S386-S393. (Pubitemid 351717326)
60. Laganas V, Alder J, Silverman JA. In vitro bactericidal activities of daptomycin against Staphylococcus aureus and Enterococcus faecalis are not mediated by inhibition of lipoteichoic acid biosynthesis. Antimicrob Agents Chemother. 2003;47(8):2682-2684. (Pubitemid 36919481)
61. Cui L, Tominaga E, Neoh H, Hiramatsu K. Correlation between reduced daptomycin susceptibility and vancomycin resistance in vancomycinintermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50(3):1079-1082. (Pubitemid 43327815)
62. Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol. 2006;44(2):655-656. (Pubitemid 43222276)
63. Fowler V Jr, Boucher H, Corey G, et al. S. aureus Endocarditis and Bacteremia Study Group. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7): 653-665.
64. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skinstructure infections. Clin Infect Dis. 2004;38(12):1673-1681. (Pubitemid 38781657)
65. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of communityacquired pneumonia. Clin Infect Dis. 2008;46(8):1142-1151. (Pubitemid 351589895)
66. Hayes D Jr, Anstead MI, Kuhn RJ. Eosinophilic pneumonia induced by daptomycin. J Infect. 2007;54(4):e211-e213.
67. Miller BA, Gray A, LeBlanc TW, Sexton DJ, Martin AR, Slama TG. Acute eosinophilic pneumonia secondary to daptomycin: a report of three cases. Clin Infect Dis. 2010;50(11):e63-e68.
68. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother. 1999;43(4):738-744. (Pubitemid 29165733)
69. Rose WE, Rybak MJ. Tigecycline: first of a new class of antimicrobial agents. Pharmacotherapy. 2006;26(8):1099-1110. (Pubitemid 44167819)
70. Stein GE, Craig WA. Tigecycline: a critical analysis. Clin Infect Dis. 2006;43(4):518-524. (Pubitemid 44157163)
71. Rodvold KA, Gotfried MH, Cwik M, Korth-Bradley JM, Dukart G, Ellis-Grosse EJ. Serum, tissue and body fluid concentrations of tigecy-cline after a single 100 mg dose. J Antimicrob Chemother. 2006;58(6):1221-1229. (Pubitemid 44884142)
72. Meagher AK, Ambrose PG, Grasela TH, Grosse JE. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005;41(suppl 5):S333-S340. (Pubitemid 41170380)
73. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother. 2005;49(11):4658-4666. (Pubitemid 41552597)
74. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68(2):140-151.
75. Curcio D. Tigecycline for severe infections: the gap between the warning and the necessity. J Antimicrob Chemother. 2011;66(2):454-456.
76. Study evaluating safety and efficacy of tigecycline versus imipenem/ cilastatin subjects with hospital-acquired pneumonia. ClinicalTrials.gov Web site. http://www.clinicaltrials.gov/ct2/show/NCT00707239?term=tigecycline +pneumonia&rank=1. Accessed October 24, 2011.
77. Drew RH, Perfect JR, Srinath L, Kurkimilis E, Dowzicky M, Talbot GH. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother. 2000;46(5):775-784.
78. Olsen KM, Rebuck JA, Rupp ME. Arthralgias and myalgias related to quinupristin-dalfopristin administration. Clin Infect Dis. 2001;32(4):e83-e86.
79. Kanafani ZA. Telavancin: a new lipoglycopeptide with multiple mechanisms of action. Expert Rev Anti Infect Ther. 2006;4(5):743-749. (Pubitemid 44890614)
80. Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis. 2009;49(12):1908-1914.
81. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005;40(11):1601-1607.
82. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother. 2005;49(1):195-201. (Pubitemid 40065793)
83. Bonkowski J, Daniels AR, Peppard WJ. Role of telavancin in treatment of skin and skin structure infections. Clin Cosmet Investig Dermatol. 2010;3:127-133.
84. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50(3):862-867. (Pubitemid 43327787)
85. Jacqueline C, Caillon J, Le Mabecque V, et al. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin- intermediate Staphylococcus aureus in a rabbit endocarditis model. Antimicrob Agents Chemother. 2007;51(9):3397-3400. (Pubitemid 350067563)
86. Ge Y, Biek D, Talbot GH, Sahm DF. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother. 2008;52(9):3398-3407.
87. Wilcox MH. Future gazing in the management of multiply drug-resistant gram-positive infection. J Infect. 2009;59(suppl 1):S75-S80.
88. Zhanel GG, Sniezek G, Schweizer F, et al. Ceftaroline. Drugs. 2009;69(7):809-831.
89. Biek D, Critchley IA, Riccobene TA, Thye DA. Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-gram-positive activity. J Antimicrob Chemother. 2010;65(suppl 4):iv9-iv16.
90. File TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51(12):1395-1405.
91. Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin Infect Dis. 1992;14(4):801-807.
92. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of Pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis. 2003;37(2):230-237. (Pubitemid 36930354)
93. Bowden RA, Ljungman P, Snydman DR. Transplant Infections. 3rd ed. New York, NY: Lippincott Williams & Wilkins; 2010.
94. Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis. 2009; 48(11):1596-1600.
95. Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. Impact of new clinical laboratory standards institute Streptococcus pneumoniae penicillin susceptibility testing breakpoints on reported resistance changes over time. Microb Drug Resist. 2011;17(1):47-52.
96. Hakenbeck R, Briese T, Chalkley L, et al. Antigenic variation of penicillin- binding proteins from penicillin-resistant clinical strains of Streptococcus pneumoniae. J Infect Dis. 1991;164(2):313-319.
97. Canu A, Malbruny B, Coquemont M, Davies TA, Appelbaum PC, Leclercq R. Diversity of ribosomal mutations conferring resistance to macrolides, clindamycin, streptogramin, and telithromycin in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2002;46(1):125-131. (Pubitemid 34031613)
98. Reinert RR, Jacobs MR, Appelbaum PC, et al. Relationship between the original multiply resistant South African isolates of Streptococcus pneumoniae from 1977 to 1978 and contemporary international resistant clones. J Clin Microbiol. 2005;43(12):6035-6041. (Pubitemid 43100657)
99. Mera RM, Miller LA, Amrine-Madsen H, Sahm DF. The impact of the pneumococcal conjugate vaccine on antimicrobial resistance in the United States since 1996: evidence for a significant rebound by 2007 in many classes of antibiotics. Microb Drug Resist. 2009;15(4):261-268.
100. Cunha BA. Antimicrobial therapy of multidrug-resistant Strepto- coccus pneumoniae, vancomycin-resistant enterococci, and methicillinresistant Staphylococcus aureus. Med Clin North Am. 2006;90(6):1165-1182. (Pubitemid 44751031)
101. Tunkel AR, Hartman BJ, Kaplan SL, et al. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis. 2004;39(9):1267-1284. (Pubitemid 39458512)
102. Garau J. Treatment of drug-resistant pneumococcal pneumonia. Lancet Infect Dis. 2002;2(7):404-415. (Pubitemid 34693258)
103. Fuller JD, Low DE. A review of Streptococcus pneumoniae infection treatment failures associated with fluoroquinolone resistance. Clin Infect Dis. 2005;41(1):118-121. (Pubitemid 40863754)
104. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44(suppl 2):S27-S72. (Pubitemid 46290553)
105. Owens RC, Ambrose PG. Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis. 2005;41(suppl 2):S144-S157. (Pubitemid 40962485)
106. Eliopoulos GM. Quinolone resistance mechanisms in pneumococci. Clin Infect Dis. 2004;38(suppl 4):S350-S356.
107. Olive D, Georges H, Devos P, et al. Severe pneumococcal pneumonia: impact of new quinolones on prognosis. BMC Infect Dis. 2011;11(1):66.
108. Kosowska-Shick K, McGhee P, Appelbaum P. Affinity of ceftaroline and other β-lactams for penicillin-binding proteins from Staphylococcus aureus and Streptococcus pneumoniae. Antimicrob Agents Chemother. 2010; 54(5):1670-1677.
109. Saravolatz LD, Stein GE, Johnson LB. Ceftaroline: a novel cephalosporin with activity against methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2011;52(9):1156-1163.
110. Gentry-Nielsen MJ, Olsen KM, Preheim LC. Pharmacodynamic activity and efficacy of linezolid in a rat model of pneumococcal pneumonia. Antimicrob Agents Chemother. 2002;46(5):1345.
111. Cammarata SK, San Pedro GS, Timm JA, et al. Comparison of linezolid versus ceftriaxone/cefpodoxime in the treatment of hospitalized patients with community-acquired pneumonia [abstract]. In: Abstracts of the European Congress of Clinical Microbiology and Infectious Diseases. Stockholm, Sweden: 2000.
112. Krause KM, Renelli M, Difuntorum S, Wu TX, Debabov DV, Benton BM. In vitro activity of telavancin against resistant gram-positive bacteria. Antimicrob Agents Chemother. 2008:52(7): 2642-2647.
113. Stucki A, Gerber P, Acosta F, Cottagnoud M, Cottagnoud P. Efficacy of telavancin against penicillin-resistant pneumococci and Staphylococcus aureus in a rabbit meningitis model and determination of kinetic parameters. Antimicrob Agents Chemother. 2006;50(2):770-773. (Pubitemid 43190998)
114. Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis. 2005;52(3):187-193. (Pubitemid 41133544)
115. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically: Approved Standard-Eighth Edition. Wayne, PA: Clinical and Laboratory Standards Institute; 2009. http://www.clsi.org/source/orders/free/m07-a8.pdf. Accessed November 16, 2011.
116. Uttley A, Collins C, Naidoo J, George R. Vancomycin-resistant enterococci. Lancet. 1988;1(8575):57-58. (Pubitemid 18017235)
117. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004;39(3):309-317. (Pubitemid 39050477)
118. Erlandson KM, Sun J, Iwen PC, Rupp ME. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia. Clin Infect Dis. 2008;46(1):30-36. (Pubitemid 351263556)
119. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy. 2006;26(3):347-352. (Pubitemid 43334674)
120. Rybkine T, Mainardi JL, Sougakoff W, Collatz E, Gutmann L. Penicillin- binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of β-lactam resistance. J Infect Dis. 1998;178(1):159-163. (Pubitemid 28328088)
121. Zscheck K, Murray B. Genes involved in the regulation of β-lactamase production in enterococci and staphylococci. Antimicrob Agents Chemother. 1993;37(9):1966-1970. (Pubitemid 23265561)
122. Noble W, Virani Z, Cree RGA. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. 1992;93(2):195-198.
123. Arthur M, Courvalin P. Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 1993;37(8):1563-1571. (Pubitemid 23226362)
124. Deshpande LM, Fritsche TR, Moet GJ, Biedenbach DJ, Jones RN. Antimicrobial resistance and molecular epidemiology of vancomycinresistant enterococci from North America and Europe: a report from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis. 2007;58(2):163-170. (Pubitemid 46856806)
125. Bonten MJM, Slaughter S, Ambergen AW, et al. The role of "colonization pressure" in the spread of vancomycin-resistant enterococci: an important infection control variable. Arch Intern Med. 1998;158(10):1127-1132.
126. Fridkin SK, Edwards JR, Courval JM, et al. The effect of vancomycin and third-generation cephalosporins on prevalence of vancomycinresistant enterococci in 126 US adult intensive care units. Ann Intern Med. 2001;135(3):175-183.
127. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis. 2004;38(suppl 4):S341-S345. (Pubitemid 38669889)
128. Ostrowsky BE, Trick WE, Sohn AH, et al. Control of vancomycinresistant Enterococcus in health care facilities in a region. N Engl J Med. 2001;344(19):1427-1433. (Pubitemid 32402099)
129. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med. 1996;335(19):1445-1453.
130. Gold HS. Vancomycin-resistant enterococci: mechanisms and clinical observations. Clin Infect Dis. 2001;33(2):210-219. (Pubitemid 32643336)
131. Linden PK. Treatment options for vancomycin-resistant enterococcal infections. Drugs. 2002;62(3):425-441. (Pubitemid 34211023)
132. Howe RA, Robson M, Oakhill A, Cornish JM, Millar MR. Successful use of tetracycline as therapy of an immunocompromised patient with septicaemia caused by a vancomycin-resistant Enterococcus. J Antimicrob Chemother. 1997;40(1):144-145. (Pubitemid 27341652)
133. Linden PK, Miller CB. Vancomycin-resistant enterococci: the clinical effect of a common nosocomial pathogen. Diagn Microbiol Infect Dis. 1999;33(2):113-120. (Pubitemid 29115040)
134. Linden P, Coley K, Kusne S. Bacteriologic efficacy of nitrofurantoin for urinary tract infection due to vancomycin-resistant Enterococcus faecium [abstract 208]. Clin Infect Dis. 1999;29(4):999.
135. Swaminathan S, Alangaden GJ. Treatment of resistant enterococcal urinary tract infections. Curr Infect Dis Rep. 2010;12(6):455-464.
136. Moellering R. Antimicrobial susceptibility of enterococci: in vitro studies of the action of antibiotics alone and in combination. In: Treatment of Infective Endocarditis. New York, NY: Grune & Stratton; 1981:81-96.
137. Hendlin D, Stapley EO, Jackson M, et al. Phosphonomycin, a new antibiotic produced by strains of Streptomyces. Science. 1969;166(901):122-123.
138. Barry A, Brown S. Antibacterial spectrum of fosfomycin trometamol. J Antimicrob Chemother. 1995;35(1):228-230.
139. Okazaki M, Suzuki K, Asano N, et al. Effectiveness of fosfomycin combined with other antimicrobial agents against multidrug-resistant Pseudomonas aeruginosa isolates using the efficacy time index assay. J Infect Chemother. 2002;8(1):37-42. (Pubitemid 34456578)
140. Falagas ME, Kastoris AC, Karageorgopoulos DE, Rafailidis PI. Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting gram-negative bacilli: a systematic review of microbiological, animal and clinical studies. Int J Antimicrob Agents. 2009;34(2):111-120.
141. Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA, Schentag JJ. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, synercid®) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagn Microbiol Infect Dis. 1998;31(3):437-451. (Pubitemid 28318625)
142. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH; Synercid Emergency-Use Study Group. The efficacy and safety of quinupristin/ dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother. 1999;44(2):251-261. (Pubitemid 29389289)
143. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program. Clin Infect Dis. 2003;36(2):159-168. (Pubitemid 36143412)
144. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. Clin Infect Dis. 2001;32(9):1373-1375. (Pubitemid 32405913)
145. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and-resistant strains. Antimicrob Agents Chemother. 2000;44(4):1062-1066. (Pubitemid 30165292)
146. Pankey G, Ashcraft D, Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother. 2005;49(12):5166-5168. (Pubitemid 41778943)
147. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect. 2007;54(6):567-571. (Pubitemid 46731225)
148. Figueroa D, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis. 2009;49(2):177-180.
149. Florescu I, Beuran M, Dimov R, et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother. 2008;62(suppl 1):17-28.
150. Gardiner D, Dukart G, Cooper A, Babinchak T. Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis. 2010;50(2):229-238.
151. Gerber P, Stucki A, Acosta F, Cottagnoud M, Cottagnoud P. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother. 2006;57(4):720-723.
152. Vázquez EG, Mensa J, López Y, et al. Penetration of linezolid into the anterior chamber (aqueous humor) of the human eye after intravenous administration. Antimicrob Agents Chemother. 2004;48(2):670-672. (Pubitemid 38141742)
153. Myrianthefs P, Markantonis SL, Vlachos K, et al. Serum and cerebrospinal fluid concentrations of linezolid in neurosurgical patients. Antimicrob Agents Chemother. 2006;50(12):3971-3976. (Pubitemid 44865137)
154. Rupprecht TA, Pfister HW. Clinical experience with linezolid for the treatment of central nervous system infections. Eur J Neurol. 2005;12(7):536-542. (Pubitemid 40956811)
155. Maure B, Martinez-Vazquez C, Perez-Veloso M, Rodriguez Fernandez M, Sopena B. Linezolid in postneurosurgical infections. Infection. 2008;36(1):82-83.